Physician profile
Michael J Ross
NPI 1740446806
$1,889.36
in general payments reported to CMS, 2019-2025
31 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $154 · 2021: $357 · 2022: $302 · 2023: $175 · 2024: $470 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $780.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $277.39 | 2019-2025 | Xyosted |
| Teleflex LLC | $159.39 | 2021-2024 | Urolift |
| Biosense Webster, INC. | $145.56 | 2024 | Carto 3 |
| Heartflow, INC. | $133.76 | 2022 | |
| Boston Scientific Corporation | $109.01 | 2021-2024 | Rezum Generator |
| Kerecis Limited | $95.61 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Procept Biorobotics Corporation | $78.78 | 2021-2024 | Aquabeam System |
| Blue Earth Diagnostics | $72.98 | 2019-2021 | |
| Laborie Medical Technologies Corp. | $70.52 | 2021-2023 | |
| 180 Medical, INC. | $66.24 | 2019-2023 | |
| Astellas Pharma US INC | $61.10 | 2020-2022 | |
| Tolmar Pharmaceuticals, INC. | $56.51 | 2019-2021 | |
| Csl Behring | $50.63 | 2019-2020 | |
| Smith+Nephew, INC. | $48.48 | 2025 | Stravix Pl |
| Pfizer INC. | $48.18 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $41.67 | 2021-2023 | Lynparza, Keytruda |
| Becton, Dickinson and Company | $38.95 | 2025 | Bard Urinary Drainage Bag, Magic3 Intermittent Catheter |
| Abbott Laboratories | $37.10 | 2021-2024 | Cardiomems |
| Bayer Healthcare Pharmaceuticals INC. | $36.71 | 2019-2020 | |
| C. R. Bard, INC. & Subsidiaries | $35.23 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $33.10 | 2024-2025 | |
| Olympus America INC. | $29.93 | 2023 | Itind System, Soltive |
| Axonics, INC. | $28.29 | 2022 | |
| Dentsply Ih INC. | $26.78 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $22.44 | 2024 | |
| Genzyme Corporation | $20.60 | 2022 | |
| Medtronic, INC. | $14.42 | 2022 | |
| Neotract INC. | $13.64 | 2020 | |
| Convatec INC. | $12.83 | 2021 | |
| Janssen Biotech, INC. | $11.82 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $11.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.